Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2022

View Archived Issues

Fgg-impaired zebrafish present dysfibrinogenemia

PDE5A targeting enhances chemotherapy efficacy in esophageal adenocarcinoma

Amylyx sponsors research at SRI on Bax and Bak inhibitors for ALS and neurodegenerative diseases

Novel orally active NLRP3 inflammasome inhibitor alleviates DSS-induced colitis in mice

Medshine Discovery patents IRAK4 and BTK inhibitors

Inventiosbio discloses new TYK2 inhibitors

Abbisko Therapeutics describes new GTPase KRAS inhibitors

Jiangsu Tasly Diyi Pharmaceutical presents new FXR agonists

Chinese researchers synthesize new vasopressin receptor antagonists

Targeting GABA-transported GAT-3 in astrocytes reduces negative outcomes of brain injury

Organoid efficacy data leads to approval of clinical trial of rare disease drug

Researchers unveil novel markers involved in pulmonary embolism

Novel HDAC3 inhibitor shows antitumor activity in 4T1-Luc xenograft mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...